Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals

Journal of NeuroVirology

Volumn 9, Issue 3, 2003, Pages 291-299

  Kivisäkk, Pia ^a   Trebst, Corinna ^a   Lee, Jar Chi ^a   Tucky, Barbara H ^a   Rudick, Richard A ^a   Campbell, James J ^b   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CD4+ T cells; Chemokine receptors; Healthy volunteers; Longitudinal

Indexed keywords

CD4 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; LONGITUDINAL STUDY; MALE; MONONUCLEAR CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REGULATORY MECHANISM; T LYMPHOCYTE; VOLUNTEER;

EID: 0038107691     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280390201001     Document Type: Article

References (45)

1. Balashov KE, Rottman JB, Weiner HL, Hancock WW (1999). CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 96: 6873-6878.
2. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR (1997). The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 94: 1925-1930.
3. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, Charo IF (1997). Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100: 2552-2561.
4. Brühl H, Wagner K, Kellner H, Schattenkirchner M, Schlondorff D, Mack M (2001). Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases. Clin Exp Immunol 126: 551-559.
5. Calabresi PA, Martin R, Jacobson S (1999). Chemokines in chronic progressive neurological diseases: HTLV-1 associated myelopathy and multiple sclerosis. J Neuro Virol 5: 102-108.
6. Campbell JD, Stinson MJ, Simons FE, Rector ES, Hay-Glass KT (2001). In vivo stability of human chemokine and chemokine receptor expression. Hum Immunol 62: 668-678.
7. Crucian B, Dunne P, Friedman H, Ragsdale R, Pross S, Widen R (1995). Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol 2: 249-252.
8. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
9. Fife BT, Huffnagle GB, Kuziel WA, Karpus WJ (2000). CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 192: 899-905.
10. Frade JM, Mellado M, del Real G, Gutierrez-Ramos JC, Lind P, Martinez A (1997). Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J Immunol 159: 5576-5584.
11. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD (2000). Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 192: 1075-1080.
12. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, Wu L, Butcher EC (2001). Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest 108: 1331-1339.
13. Kivisäkk P, Liu Z, Trebst C, Tucky BH, Wu L, Stine J, Mack M, Rudick RA, Campbell JJ, Ransohoff RM (2002a). Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods 29: 319-325.
14. Kivisäkk P, Trebst C, Eckstein DJ, Kerza-Kwiatecki AP, Ransohoff RM (2001). Chemokine-based therapies for MS: how do we get there from here? Trends Immunol 22: 591-593.
15. Kivisäkk P, Trebst C, Liu Z, Tucky BH, Sørensen TL, Rudick RA, Mack M, Ransohoff RM (2002b). T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol 129: 510-518.
16. Kunkel EJ, Boisvert J, Murphy K, Vierra MA, Genovese MC, Wardlaw AJ, Greenberg HB, Hodge MR, Wu L, Butcher EC, Campbell JJ (2002). Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 160: 347-355.
17. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW (1999). Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 274: 9617-9626.
18. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
19. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996a). Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 963-969.
20. Loetscher M, Loetscher P, Brass N, Meese E, Moser B (1998). Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28: 3696-3705.
21. Loetscher P, Seitz M, Baggiolini M, Moser B (1996b). Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 184: 569-577.
22. Luster AD (1998). Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 338: 436-445.
23. Mack M, Brühl H, Gruber R, Jaeger C, Cihak J, Eiter V, Plachy J, Stangassinger M, Uhlig K, Schattenkirchner M, Schlondorff D (1999). Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum 42: 981-988.
24. Martinez-Caceres EM, Barrau MA, Brieva L, Espejo C, Barbera N, Montalban X (2002). Treatment with methyl-prednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects. Clin Exp Immunol 127: 165-171.
25. Misu T, Onodera H, Fujihara K, Matsushima K, Yoshie O, Okita N, Takase S, Itoyama Y (2001). Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. J Neuroimmunol 114: 207-212.
26. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Pawer CA (2000). International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52: 145-176.
27. Porrini AM, Gambi D, Malatesta G (1992). Memory and naive CD4+ lymphocytes in multiple sclerosis. J Neurol 239: 437-440.
28. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998). The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101: 746-754.
29. Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM (1999). Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 162: 3840-3850.
30. Ransohoff RM, Bacon KB (2000). Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs 9: 1079-1097.
31. Sallusto F, Kremmer E, Palermo B, Hoy A, Ponath P, Qin S, Forster R, Lipp M, Lanzavecchia A (1999). Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 29: 2037-2045.
32. Sallusto F, Mackay CR, Lanzavecchia A (2000). The role of chemokine receptors in primary, effector, and memory immune responses. Anna Rev Immunol 18: 593-620.
33. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M (1996). Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35: 3362-3367.
34. Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodroofe MN (2000a). Expression of the betachemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 108: 192-200.
35. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN (2000b). Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 26: 133-142.
36. Sørensen TL, Sellebjerg F (2001). Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 57: 1371-1376.
37. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM (1999). Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103: 807-815.
38. Sørensen TL, Trebst C, Kivisäkk P, Klaege KL, Majmudar A, Ravid R, Lassmann H, Olsen DB, Strieter RM, Ransohoff RM, Sellebjerg F (2002). Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 127: 59-68.
39. Springer TA (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301-314.
40. Strunk T, Bubel S, Mascher B, Schlenke P, Kirchner H, Wandinger KP (2000). Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor-alpha-secreting T lymphocytes in multiple sclerosis patients. Ann Neurol 47: 269-273.
41. Teleshova N, Pashenkov M, Huang YM, Söderström M, Kivisäkk P, Kostulas V, Haglund M, Link H (2002). Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol 249: 723-729.
42. Trebst C, Sørensen TL, Kivisäkk P, Cathcart MK, Hesselgesser J, Horuk R, Sellebjerg F, Lassmann H, Ransohoff RM (2001). CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 159: 1701-1710.
43. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, Mackay CR (1997). CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1 in vitro. J Exp Med 185: 1681-1691.
44. Wu XM, Osoegawa M, Yamasaki K, Kawano Y, Ochi H, Horiuchi I, Minohara M, Ohyagi Y, Yamada T, Kira JI (2000). Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets. J Neurol Sci 177: 24-31.
45. Zang YC, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM, Zhang JZ (2000). Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain 123 (Pt 9): 1874-1882.